Oncothyreon (ONTY +16%) is higher today on a rumor that Phase III results of its cancer...

|By:, SA News Editor

Oncothyreon (ONTY +16%) is higher today on a rumor that Phase III results of its cancer treatment drug Stimuvax are meeting endpoints. The stock has been heavily shorted recently - short interest now averages 2+ days to cover - adding to the stock's volatility.